Rocket Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 62.05 million compared to USD 58.34 million a year ago. Basic loss per share from continuing operations was USD 0.66 compared to USD 0.73 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.53 USD | +0.47% |
|
-4.23% | -28.16% |
06-28 | Needham Trims Price Target on Rocket Pharmaceuticals to $52 From $53, Maintains Buy Rating | MT |
06-28 | Rocket Pharmaceuticals Says FDA Seeks More Information on Kresladi | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.16% | 1.95B | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- RCKT Stock
- News Rocket Pharmaceuticals, Inc.
- Rocket Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024